Rhythm Pharmaceuticals (RYTM) Total Current Liabilities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Total Current Liabilities data on file, last reported at $103.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $103.2 million, down 7.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.2 million (down 7.71% YoY), and the FY2025 annual result was $105.9 million, down 8.29% from the prior year.
• Total Current Liabilities fell to $103.2 million in Q1 2026 per RYTM's latest filing, from $105.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $129.5 million in Q2 2025 and troughed at $33.1 million in Q3 2022.
• A 5-year average of $72.9 million and a median of $54.7 million in 2024 frame the typical range for Total Current Liabilities.
• On a YoY basis, Total Current Liabilities climbed as much as 180.56% in 2022 and fell as far as 8.33% in 2022.
• A 5-year view of Total Current Liabilities shows it stood at $39.8 million in 2022, then jumped by 38.67% to $55.2 million in 2023, then jumped by 109.26% to $115.5 million in 2024, then fell by 8.29% to $105.9 million in 2025, then slipped by 2.59% to $103.2 million in 2026.
• Business Quant data shows RYTM's Total Current Liabilities at $103.2 million in Q1 2026, $105.9 million in Q4 2025, and $104.3 million in Q3 2025.